AstraZeneca Boosts Cancer Arsenal With 55% Acerta Pharma StakeMani
AstraZeneca said Thursday it would buy 55% of privately held biotech firm Acerta Pharma for $4 billion to bolster the UK pharmaceutical giant’s blood cancer treatment portfolio.
The latest deal caps an intense period of deal making for the UK drug maker as it races to refill its drug portfolio.
AstraZeneca unveils strategic transaction with Acerta Pharma
The latest deal envisages AstraZeneca paying an upfront payment of $2.5 billion for the stake and then a further unconditional $1.5 billion upon receipt . . .
This content is exclusively for paying members. Access all of our content on including years of timeless investment news and in depth analysis for only a few dollars a month by signing up here while also supporting quality content and journalism, or learn more about our premium content here
If you are subscribed and having an account error please clear cache and then cookies if that does not work email firstname.lastname@example.org and we will get back to you as quick as humanly possible